Beam Therapeutics Inc. (BEAM)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. John M. Evans M.B.A. | CEO & Director | 1.11M | 9.03M | 1978 |
Dr. Giuseppe Ciaramella Ph.D. | President | 933.2k | 1.27M | 1969 |
Ms. Terry-Ann Burrell M.B.A. | CFO & Treasurer | 711.15k | -- | 1977 |
Dr. Feng Zhang Ph.D. | Co-Founder | -- | -- | -- |
Dr. David R. Liu Ph.D. | Co-Founder | -- | -- | -- |
Dr. J. Keith Joung M.D., Ph.D. | Co-Founder | -- | -- | -- |
Dr. Nicole Gaudelli Ph.D. | Co-Founder | -- | -- | -- |
Dr. Alexis Komor Ph.D. | Co-Founder | -- | -- | -- |
Dr. Manmohan Singh Ph.D. | Chief Technology Officer | -- | -- | -- |
Dr. Gopi Shanker Ph.D. | Chief Scientific Officer | -- | -- | -- |
Beam Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 436
Description
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Corporate Governance
Recent Events
- Apr 19, 2024DEFA14A: Proxy StatementsSee Full Filing
- Feb 28, 2024S-3ASR: Offering RegistrationsSee Full Filing
- Feb 27, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 25, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 24, 2024SC 13G: Tender Offer/Acquisition ReportsSee Full Filing